The DAPA-HF (dapagliflozin) trial (in which the enrolled subjects had a better median ejection fraction and were not on aldosterone antagonists nor neprilysin inhibitors) also showed a reduction in HF events irrespective of their diabetic status (Packer et al., 2020). This evidence concerns the gene MME and hydrops fetalis.